GO:0008239 dipeptidyl-peptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008239 dipeptidyl-peptidase activity describes the catalysis of hydrolysis of N-terminal dipeptides from a polypeptide chain.
• This activity is central to protein maturation, degradation, and the generation of bioactive peptides, including N-truncated amyloid-beta.
• Key enzymes include DPP4, DPP1 (CTSC), DPP3, and meprin beta, which are implicated in diabetes, cancer, and Alzheimer's disease [2,3,4,6].
• Dipeptidyl peptidase activity can be regulated by endogenous inhibitors and is a target for drugs such as brensocatib and sitagliptin [1,3].
• CRISPR knockout, point mutation, and overexpression models are essential to dissect the physiological roles of these enzymes.
• EDITGENE provides custom cell models and screening services to study dipeptidyl-peptidase activity in disease contexts.
Description
Dipeptidyl-peptidase activity (GO:0008239) is a molecular function defined as the catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain. This exopeptidase activity is critical for protein turnover, post-translational processing, and the generation of short bioactive peptides that act in metabolic, immune, and neurological pathways [2,4]. Researchers study this activity to understand how proteolytic processing contributes to both normal physiology and disease, such as type 2 diabetes mellitus and Alzheimer's disease [3,4]. The enzymes exhibiting this activity, including dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 1 (CTSC), and meprin beta, are widely expressed and have distinct substrate specificities and cellular localizations [2,6]. Because of their roles in disease, these enzymes are attractive targets for therapeutic intervention, as demonstrated by DPP4 inhibitors for diabetes and brensocatib for bronchiectasis [1,3]. Understanding the molecular mechanisms, regulation, and disease associations of dipeptidyl-peptidase activity is therefore a major focus of biomedical research [5,6].
dipeptidyl-peptidase activity At A Glance
| GO ID | GO:0008239 |
|---|---|
| GO term | dipeptidyl-peptidase activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain. |
| Major function | Proteolytic processing and degradation of peptides and proteins. |
| EC number | 3.4.14.- |
| Substrates | Polypeptides with free N-termini, including chemokines, incretins, and amyloid-beta. |
| Inhibitors | Brensocatib, sitagliptin, and other DPP4 inhibitors. |
What Is GO:0008239?
According to the Gene Ontology, dipeptidyl-peptidase activity (GO:0008239) is the catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain. This means the enzyme cleaves a dipeptide (two amino acids) from the amino terminus of a protein or peptide substrate, leaving the remainder of the chain intact. This activity is distinct from endopeptidases, which cleave internal peptide bonds, and from aminopeptidases, which remove single amino acids. The reaction typically occurs in a stepwise manner and can be processive, releasing multiple dipeptides from the same substrate.
Why Is dipeptidyl-peptidase activity Important in Cell Biology?
Dipeptidyl-peptidase activity is important because it regulates the half-life and activity of numerous bioactive peptides, including hormones, chemokines, and neuropeptides [2,4]. Dysregulation of this activity contributes to metabolic disorders such as type 2 diabetes mellitus, inflammatory diseases like bronchiectasis, and neurodegenerative conditions such as Alzheimer's disease [1,3,4]. Moreover, dipeptidyl peptidases are therapeutic targets; inhibitors like sitagliptin and brensocatib have shown clinical benefit [1,3]. Studying this activity helps researchers understand protein processing pathways and develop new treatments.
• Regulates the activity of incretin hormones (GLP-1, GIP) and glucose homeostasis.
• Modulates chemokine activity and immune cell recruitment.
• Contributes to the N-truncation of amyloid-beta, a key event in Alzheimer's disease.
• Involved in cancer progression through altered expression of DPP4 and related enzymes.
• Target for brensocatib in bronchiectasis to reduce neutrophil serine protease activity.
• Essential for protein catabolism and amino acid recycling.
• Plays a role in small RNA association via Argonaute processing.
• Aging is associated with increased dipeptidyl peptidase I activity in leucocytes.
• Dietary polyphenols can inhibit DPP4, offering nutritional intervention strategies.
• Meprin beta dipeptidyl-peptidase activity links amyloid-beta truncation to pGlu-Abeta formation.
What Happens During dipeptidyl-peptidase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the end of a protein chain.
Dipeptidyl peptidases recognize substrates by binding to the N-terminus of a polypeptide chain. The enzyme active site accommodates the first two amino acids, positioning the scissile bond for hydrolysis. Substrate specificity varies among family members; for example, DPP4 prefers proline or alanine at the second position, while meprin beta has broader specificity.
Catalytic cleavage of the dipeptide
In simple terms: The enzyme cuts off a two-amino-acid piece.
The catalytic mechanism involves a serine or cysteine protease-like triad that activates a water molecule to hydrolyze the peptide bond between the second and third amino acids, releasing the N-terminal dipeptide [1,4]. This reaction is processive for some enzymes, allowing sequential removal of dipeptides.
Product release and downstream effects
In simple terms: The cut pieces are released and can have their own functions.
The released dipeptide and the truncated substrate can have distinct biological activities. For instance, N-truncated amyloid-beta is a substrate for glutaminyl cyclase, leading to pGlu-Abeta formation, which is linked to Alzheimer's disease. In the immune system, truncation of chemokines by DPP4 alters their receptor specificity and activity.
Regulation by inhibitors and cellular localization
In simple terms: The enzyme's activity is controlled by where it is and what molecules block it.
Dipeptidyl peptidase activity is regulated by endogenous inhibitors, such as protease inhibitors, and by cellular localization. For example, DPP4 is a membrane-bound enzyme that can be cleaved to a soluble form. Brensocatib inhibits DPP1 (CTSC), reducing the activity of neutrophil serine proteases in bronchiectasis patients.
Key Genes Involved in GO:0008239 dipeptidyl-peptidase activity
The following genes encode enzymes that exhibit dipeptidyl-peptidase activity or are directly involved in its regulation and downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DPP4 | Serine exopeptidase that cleaves dipeptides from peptides with Pro/Ala at P1 | Target for type 2 diabetes; regulates incretins and chemokines [2,3] |
| CTSC (DPP1) | Cysteine protease that activates neutrophil serine proteases | Target for bronchiectasis; inhibitor brensocatib in clinical trials |
| DPP3 | Zinc-dependent exopeptidase involved in protein turnover | Emerging role in cardiovascular and neurological diseases |
| MEP1B (meprin beta) | Metalloprotease with dipeptidyl-peptidase activity | Links Abeta N-truncation to pGlu-Abeta formation in Alzheimer's disease |
| AGO2 | Argonaute protein processed by dipeptidyl peptidases | Controls small RNA association and gene silencing |
| AGO1 | Argonaute protein subject to proteolytic processing | Regulates RNA interference pathways |
| AGO3 | Argonaute protein with potential dipeptidyl peptidase cleavage sites | Implicated in small RNA biology |
| AGO4 | Argonaute protein involved in transcriptional silencing | May be processed by dipeptidyl peptidases |
| FAP | Seprase with dipeptidyl peptidase activity | Expressed in cancer stroma; potential target |
| DPP8 | Intracellular dipeptidyl peptidase | Regulates immune signaling and cell death |
| DPP9 | Intracellular dipeptidyl peptidase | Involved in inflammasome regulation |
| PREP | Prolyl endopeptidase with dipeptidyl peptidase-like activity | Linked to memory and neurodegeneration |
| ANPEP | Aminopeptidase N with dipeptidyl peptidase activity | Marker in cancer and immune cells |
| XPNPEP1 | X-prolyl aminopeptidase with dipeptidyl peptidase activity | Role in peptide processing |
| CTSL | Cathepsin L, can exhibit dipeptidyl peptidase activity | Involved in antigen presentation |
| CTSS | Cathepsin S, with dipeptidyl peptidase activity | Linked to autoimmune diseases |
| ACE2 | Angiotensin-converting enzyme 2, has dipeptidyl peptidase activity | Receptor for SARS-CoV-2; regulates blood pressure |
| PRCP | Prolylcarboxypeptidase with dipeptidyl peptidase activity | Regulates angiotensin and bradykinin |
How Is dipeptidyl-peptidase activity Regulated?
Dipeptidyl-peptidase activity is regulated at multiple levels. Transcriptionally, expression of DPP4 and related genes varies by tissue and disease state. Post-translationally, proteolytic cleavage can release soluble forms of membrane-bound enzymes, altering their localization and substrate access. Endogenous inhibitors, such as protease inhibitors, can modulate activity. Additionally, pharmacological inhibitors like brensocatib and sitagliptin specifically block DPP1 and DPP4, respectively, demonstrating the druggability of this activity [1,3].
dipeptidyl-peptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DPP4 | Type 2 diabetes mellitus | Knockout mouse or cell line; overexpression for incretin studies |
| CTSC (DPP1) | Bronchiectasis, inflammation | Knockout neutrophils; point mutation to abolish catalytic activity |
| MEP1B | Alzheimer's disease | Knock-in of human APP with meprin beta cleavage site |
| DPP3 | Cardiovascular disease | Knockout zebrafish or mouse; overexpression in cardiomyocytes |
| FAP | Cancer | Knockout cancer-associated fibroblasts; overexpression in tumor cells |
Dipeptidyl-peptidase activity in type 2 diabetes mellitus
DPP4 inhibitors are a major class of oral antidiabetic drugs because they prevent the degradation of incretin hormones GLP-1 and GIP, thereby enhancing insulin secretion. Dietary polyphenols have also been shown to inhibit DPP4, offering a nutritional approach to glycemic control. Thus, dipeptidyl-peptidase activity is directly linked to glucose homeostasis and diabetes pathogenesis.
Dipeptidyl-peptidase activity in Alzheimer's disease
Meprin beta exhibits dipeptidyl-peptidase activity that N-truncates amyloid-beta, generating a substrate for glutaminyl cyclase, which produces pGlu-Abeta, a toxic species in Alzheimer's disease. This links dipeptidyl-peptidase activity to amyloid plaque formation and neurodegeneration.
Dipeptidyl-peptidase activity in bronchiectasis and inflammation
DPP1 (CTSC) activates neutrophil serine proteases, which drive tissue damage in bronchiectasis. Brensocatib, a DPP1 inhibitor, reduces the activity of all major neutrophil serine proteases in patients, highlighting the therapeutic potential of targeting this activity.
Dipeptidyl-peptidase activity in cancer
Expression of DPP4 and related dipeptidyl peptidases is altered in various cancers, where they can influence tumor growth, invasion, and immune evasion. For example, FAP is expressed in cancer-associated fibroblasts and promotes tumor progression.
From dipeptidyl-peptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DPP4 affect glucose tolerance? | DPP4 knockout mouse or CRISPR knockout cell line |
| Does a point mutation in the catalytic serine of CTSC abolish its activity? | Point mutation knock-in cell line |
| Can overexpression of meprin beta increase Abeta truncation? | Overexpression cell model with APP substrate |
| Does tagging DPP4 with GFP alter its localization? | Tagged knock-in cell line |
| Which genes regulate dipeptidyl-peptidase activity? | CRISPR library screening |
| What is the substrate specificity of DPP9? | Knockout cell line followed by proteomics |
How to Study the dipeptidyl-peptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic substrate assay | Enzymatic activity | Inhibitor screening for DPP4 |
| Mass spectrometry | Substrate cleavage sites | Identifying natural substrates |
| CRISPR knockout screening | Gene essentiality for activity | Discovering regulators |
| Western blot | Protein expression and processing | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Studying enzyme trafficking |
| qPCR | mRNA expression levels | Assessing transcriptional regulation |
| Enzyme-linked immunosorbent assay | Peptide product quantification | Measuring incretin levels |
Enzymatic activity assays
Dipeptidyl-peptidase activity can be measured using fluorogenic or chromogenic substrates, such as Gly-Pro-p-nitroanilide for DPP4. These assays are used to screen inhibitors and characterize enzyme kinetics.
Proteomics and substrate identification
Mass spectrometry-based proteomics can identify natural substrates and cleavage sites by comparing wild-type and knockout cells or tissues. This approach has been used to link meprin beta to amyloid-beta truncation.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate dipeptidyl-peptidase activity or mediate its downstream effects. For example, screens have revealed roles for Argonaute processing.
Imaging and localization studies
Fluorescence microscopy of tagged enzymes can reveal subcellular localization and trafficking. For instance, GFP-tagged DPP4 can be used to study its membrane dynamics.
How CRISPR Can Be Used to Study GO:0008239 dipeptidyl-peptidase activity
Knockout
CRISPR knockout of DPP4, CTSC, or MEP1B can abolish dipeptidyl-peptidase activity, allowing researchers to study loss-of-function phenotypes in diabetes, inflammation, or neurodegeneration [1,4]. Knockout cell lines are valuable for identifying specific substrates and pathways.
Point Mutation
Introducing point mutations in catalytic residues (e.g., serine to alanine) can generate enzyme-dead variants, distinguishing catalytic activity from non-catalytic functions. This is particularly useful for enzymes with dual roles.
Knock-in
Knock-in of disease-associated mutations or tags (e.g., GFP) enables tracking of enzyme localization and dynamics in live cells. Knock-in models can also humanize target genes for drug testing.
Overexpression
Overexpression of dipeptidyl peptidases such as DPP4 or meprin beta can mimic disease states and help identify downstream effects, such as increased amyloid-beta truncation. Overexpression models are also used for drug screening.
How EDITGENE Supports dipeptidyl-peptidase activity Research
Researchers studying dipeptidyl-peptidase activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for dipeptidyl-peptidase activity research.
Frequently Asked Questions About dipeptidyl-peptidase activity
What is dipeptidyl-peptidase activity?
Dipeptidyl-peptidase activity (GO:0008239) is the catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain.
What genes are involved in dipeptidyl-peptidase activity?
Key genes include DPP4, CTSC (DPP1), DPP3, MEP1B, and FAP, among others [2,4,6].
How is dipeptidyl-peptidase activity measured?
It is commonly measured using fluorogenic substrates like Gly-Pro-p-nitroanilide in enzymatic assays.
What diseases are associated with dipeptidyl-peptidase activity?
It is linked to type 2 diabetes, Alzheimer's disease, bronchiectasis, and cancer [1,3,4].
What is the role of DPP4 in diabetes?
DPP4 degrades incretin hormones; its inhibition improves glycemic control in type 2 diabetes.
How does meprin beta contribute to Alzheimer's disease?
Meprin beta N-truncates amyloid-beta, promoting pGlu-Abeta formation, a toxic species in Alzheimer's disease.
Can CRISPR be used to study dipeptidyl-peptidase activity?
Yes, CRISPR knockout, point mutation, and overexpression models are widely used to dissect gene function.
What is the difference between DPP4 and DPP1?
DPP4 is a serine exopeptidase regulating incretins, while DPP1 (CTSC) is a cysteine protease activating neutrophil serine proteases [1,2].
Are there natural inhibitors of dipeptidyl-peptidase activity?
Dietary polyphenols have been shown to inhibit DPP4, offering nutritional modulation.
How does aging affect dipeptidyl-peptidase activity?
Aging is associated with increased dipeptidyl peptidase I activity in leucocytes from healthy elderly people.
Conclusion
Dipeptidyl-peptidase activity (GO:0008239) is a fundamental proteolytic function with broad implications in metabolism, immunity, and neurodegeneration. Its enzymes are validated drug targets, and ongoing research continues to uncover new substrates and regulatory mechanisms. CRISPR-based models are indispensable for causal studies, and EDITGENE offers tailored solutions to accelerate discovery in this field.
References
- 1. Cipolla D et al.. 2023. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.. Respir Res 24(1):133 PMID: 37198686
- 2. Kotacková L et al.. 2009. Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.. Folia Biol (Praha) 55(3):77-84 PMID: 19545486
- 3. Jia Y et al.. 2023. Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods.. Crit Rev Food Sci Nutr 63(19):3452-3467 PMID: 34652225
- 4. Schlenzig D et al.. 2018. Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation.. J Alzheimers Dis 66(1):359-375 PMID: 30320570
- 5. Gudipati RK et al.. 2021. Protease-mediated processing of Argonaute proteins controls small RNA association.. Mol Cell 81(11):2388-2402.e8 PMID: 33852894
- 6. Malovan G et al.. 2023. The emerging role of dipeptidyl peptidase 3 in pathophysiology.. FEBS J 290(9):2246-2262 PMID: 35278345
- 7. Llorente L et al.. 1999. Increased collagenase and dipeptidyl peptidase I activity in leucocytes from healthy elderly people.. Clin Exp Immunol 116(3):425-9 PMID: 10361229
